Aradigm, Inhale, Bioject Update Investors at Annual Drug

                           Delivery Forum                                   November 18      FOSTER CITY, Nov. 2 /PRNewswire/ -- Biotechnology stocks are broadly  resurgent again, and the drug-delivery group is no exception.  The Third  Annual Informed Investors Bay Area Drug Delivery Stocks Forum on November 18  offers investors a full update on companies in this group.   The Forum features companies like Aradigm (Nasdaq: ARDM) and  Bioject Medical Technologies, Inc. (Nasdaq: BJCT), which are developing  alternatives for conventional, needle delivery.  It also gives investors a  broad look at the group, from inhaleable-insulin developer  Inhale Therapeutics (Nasdaq: INHL) with a market capitalization of  $2.3 billion, to tiny, emulsion-delivery firm Sonus, sporting a $6 million  market capitalization.   The Forum runs from 8:30 a.m. to 12:30 p.m. Saturday, November 18 at the  Crowne Plaza Hotel in Foster City.  The cost is $25 prepaid, $40 at the door.  More information and registration can be found at or  by calling 800-992-4683.   Aradigm Corporation is a developer of advanced pulmonary drug delivery  systems for the treatment of systemic conditions as well as lung diseases.  Aradigm's principal product development programs are based on its AERx  Pulmonary Drug Delivery System, which creates aerosols from liquid drug  formulations for delivery locally to the lung or systemically via the lung.   Inhale, located in San Carlos, Calif., is pioneering drug delivery systems  to deliver easily a range of inhaleable drugs.  Inhale now has four partnered  development projects that are in clinical testing.  They are inhaleable forms  of drugs used to treat diabetes, multiple sclerosis, osteoporosis and  emphysema.   Bioject Medical Technologies Inc. develops, manufactures and markets jet  injection systems for needle-free drug delivery.  Bioject's two core products  are the Biojector 2000 and the Vitajet.  The Biojector 2000 system is a CO2  cartridge that delivers doses of medication through the skin.  The Vitajet  serves a similar function as the Biojector, but is powered by a spring rather  than CO2. is the conduit for unfiltered communication between  individual investors and the executives of technology and biotechnology  companies.  Live virtual and onsite Forums, special webcasts, original  editorial pieces and widely followed weekly radio shows, "BioTalk" and "Tech  Check," put individual investors in the analyst's chair.      SOURCE  /CONTACT:  Brian Finnigan or Steve Chanecka, both of, 916-780-6100, or 800-992-4683/   /Web site:   (INHL ARDM BJCT)   CO:; Aradigm Corporation; Bioject Medical Technologies,    Inc.; Inhale Therapeutics  ST:  California  IN:  FIN MLM BIO  SU:  
Press spacebar to pause and continue. Press esc to stop.